FDA Issues Draft Guidance for Industry: Presenting Risk Information in Prescription Drug and Medical Device Promotion – How to Convey the Good, Bad and Ugly

Several AGG attorneys co-wrote an article for the November issue of Regulatory Focus, a publication of the Regulatory Affairs Professionals Society® (RAPS). Alan G. Minsk, Jennifer S. Blakely and Meredith M. Burris published the article, “FDA Issues Draft Guidance for Industry: Presenting Risk Information in Prescription Drug and Medical Device Promotion – How to Convey the Good, Bad and Ugly.” The piece looks at a draft guidance recently issued by the FDA on how companies in the industry should present risk information in prescription drug and medical device promotion.


Click here to view the article.